Report
Clopidogrel plus acetylsalicylic acid in acute coronary syndrome
Report documents
-
Executive summary of the final report
Clopidogrel plus acetylsalicylic acid in acute coronary syndrome
-
Final report
Clopidogrel plus acetylsalicylic acid in acute coronary syndrome
-
Documentation and appraisal of comments on the preliminary report
Clopidogrel plus acetylsalicylic acid in acute coronary syndrome
-
Preliminary report
Clopidogrel plus acetylsalicylic acid in acute coronary syndrome
-
Report plan version 2.0
Clopidogrel plus acetylsalicylic acid in acute coronary syndrome
-
Documentation and appraisal of comments on the report plan version 1.0
Clopidogrel plus acetylsalicylic acid in acute coronary syndrome
-
Amendment 2 to the report plan version 1.0
Clopidogrel plus acetylsalicylic acid in acute coronary syndrome
-
Amendment 1 to the report plan version 1.0
Clopidogrel plus acetylsalicylic acid in acute coronary syndrome
-
Report plan version 1.0
Clopidogrel plus acetylsalicylic acid in acute coronary syndrome
Press releases
Combination of ASA and clopidogrel reduces heart attack risk in patients with acute coronary syndrome
Patients particularly benefit in the early phase of treatment - however, bleeding complications occur more often
Additional information
IQWiG health information
Project details
- Project no.
- A04-01B
- Commission
- Commission awarded on 15.12.2004 by the Federal Joint Committee (GBA).
- Report type
- Report
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation